CoChat
Sign Up
Cited by 87Radiopharmaceutical Chemistry and ApplicationsAdrenal and Paraganglionic TumorsNeuroendocrine Tumor Research Advances

[131I]Iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma

Hahner, Stefanie, Kreissl, Michael C., Fassnacht, Martin, Haenscheid, Heribert, Knoedler, Pascal, Lang, Katharina, Buck, Andreas K., Reiners, Christoph +2 more·2012·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jc.2011-2765
Open this paper in CoChat — free account

Abstract

CONTEXT: In advanced adrenocortical carcinoma (ACC), many patients have progressive disease despite standard treatment, indicating a need for new treatment options. We have shown high and specific retention of [123I]metomidate ([123I]IMTO) in ACC lesions, suggesting that labeling of metomidate with 131I offers targeted radionuclide therapy for advanced ACC. OBJECTIVE: Safety and efficacy of radionuclide therapy with [131I]IMTO in advanced ACC. DESIGN/SETTING: This monocentric case series comprised 19 treatments in 11 patients with nonresectable ACC. PATIENTS AND INTERVENTION: Between 2007 and 2010, patients with advanced ACC not amenable to radical surgery and exhibiting high uptake of [123I]IMTO in their tumor lesions were offered treatment with [131I]IMTO (1.6-20 GBq in one to three cycles of [131I]IMTO). MAIN OUTCOME MEASURE: Tumor response was assessed according to response evaluation criteria in solid tumors (RECIST version 1.1) criteria, and side effects were assessed by Common Toxicity Criteria (version 4.0). RESULTS: Best response was classified as partial response in one case with a change in target lesions of -51% from baseline, as stable disease in five patients, and as progressive disease in four patients. One patient died 11 d after treatment with [131I]IMTO unrelated to radionuclide therapy. In patients responding to treatment, median progression-free survival was 14 months (range, 5-33) with ongoing disease stabilization in three patients at last follow-up. Treatment was well tolerated, but transient bone marrow depression was observed. Adrenal insufficiency developed in two patients. CONCLUSIONS: Radionuclide therapy with [131I]IMTO is a promising treatment option for selected patients with ACC, deserving evaluation in prospective clinical trials.

Integrity signals

Registry

Crossref · 10.1210/jc.2011-2765

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • [131I]IMTO treatment in 11 patients with advanced ACC resulted in median progression-free survival of 14 months in 6 patients who responded to therapy.

    “[131I]IMTO treatment in 11 patients with advanced ACC resulted in median progression-free survival for 14 months in 6 patients who responded to therapy (319).”

    From Adrenocortical carcinoma (2014) · cites this paper as [319]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Hahner, S., Kreissl, M. C., Fassnacht, M., Haenscheid, H., Knoedler, P., Lang, K., Buck, A. K., Reiners, C., Allolio, B., & Schirbel, A.
Affiliations
  • University of Würzburg (DE)
  • Universitätsklinikum Würzburg (DE)
Corresponding author
Allolio, Bruno
ORCID
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2012-03-01
Volume
97
Issue
3
Pages
914-922
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jc.2011-2765
OpenAlex
W2048467225
Cited by
87
References
35
Citations by year
2026: 2 · 2025: 7 · 2024: 4 · 2023: 5 · 2022: 6 · 2021: 7 · 2020: 8 · 2019: 3 · 2018: 2 · 2017: 5 · 2016: 7 · 2015: 11 · 2014: 6 · 2013: 11 · 2012: 3
FWCI
4.88
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
  • Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
  • Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
Keywords
adrenocortical carcinoma, targeted radionuclide therapy, iodine-131, tumor retention, treatment response, progression-free survival, bone marrow depression, adrenal insufficiency, treatment toxicity
MeSH terms
Adrenal Cortex Neoplasms, Adult, Aged, Aged, 80 and over, Etomidate, Female, Humans, Iodine Radioisotopes, Male, Middle Aged, Treatment Outcome, Adrenocortical Carcinoma, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review